Formal discussant Sharon H. Giordano, MD, MPH, Professor of Medicine and Chair of Health Services Research at The University of Texas MD Anderson Cancer Center, Houston, emphasized how important it is to preserve fertility in these younger patients with breast cancer.
“The main downside is an increase in menopausal symptoms during treatment,” she said.
Because of the missing data on 38% of participants, low accrual rates, and early termination of the trial, Dr. Giordano could not consider these results definitive.
“Having said that, I would be comfortable offering this option to my young patients who desire fertility preservation,” Dr. Giordano stated. ■
Disclosure: Dr. Giordano reported no potential conflicts of interest.
The good news for younger women with hormone receptor–negative early breast cancer is that adding goserelin (Zoladex), a luteinizing hormone–releasing hormone (LHRH) agonist, to chemotherapy can prevent sudden menopause, better preserve ovarian function and fertility, and lead to successful...